The acquisition, which involves a concurrent licensing deal with startup Mirador, gives Jasper a chance to rebound from ...
Mixed Phase 3 data for camlipixant prompted the British pharma to cease development, making the drug the third from its class to fail. The lower, 50 milligram twice-daily dose in that successful study ...
Some of the industry’s most closely-watched AI drugs could provide insight into the success of technology-assisted ...
The latest in a prolific streak of buyouts by Lilly is the strongest sign yet that large pharmaceutical companies may finally ...
The Phase 2 data exceeded expectations, lifting company shares as high as nearly $130 apiece and building the case for what ...
The speedy clearance of Lipfendra is an important milestone for Merck and the result of a controversial voucher program put in place by former FDA commissioner Marty Makary.
Still, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk. Details in the drug’s ...
The results were seen by Wall Street analysts as “direct proof-of-concept” that sac-TMT, a drug Merck views as a “cornerstone ...
The two startups are the third and fourth, respectively, to outline offerings this month and aim to capitalize on momentum ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results